Talc baby powder concerns undermine J&J's effort to bolster consumer products unit
- J&J relaunched its iconic namesake baby product line this summer to reverse a 20 percent sales decline in J&J's baby care unit since 2011.
- Reuters published a story Friday saying a review of documents showed J&J executives knew for decades its talc baby powder contained asbestos.
- J&J refuted the allegation. It has started advertising in newspapers and news websites.
This year was supposed to be a big year for Johnson & Johnson's consumer business, but fresh concern about the company's talc baby powder threatens that.
J&J relaunched its iconic namesake baby product line this summer to reverse a 20 percent sales decline in J&J's baby care unit since 2011. While trusted for decades, the 124-year-old brand had fallen out of touch with consumers, namely millennial moms, who opted instead for cleaner, natural products from trendy upstart brands.
J&J reformulated and redesigned its baby care products and introduced a new line of products made with cotton. Early data suggested J&J's efforts were working. The business posted a 20 percent increase in the third-quarter from the same time last year.
A Reuters report claiming J&J executives knew its talc baby powder contained asbestos caused the company's usually stable stock to fall 10 percent on Friday, shaving nearly $40 billion from its market value. Its shares continued to slide Monday, falling by another 3.8 percent in midday trading.
Reuters said its review showed that from 1971 to the early 2000s, J&J executives, mine managers, doctors and lawyers were aware the company's raw talc and finished powders sometimes tested positive for small amounts of asbestos.
J&J denied the allegation, saying the story was "one-sided, false and inflammatory" and an "absurd conspiracy theory," according to a statement.
The company over the weekend published a point-by-point rebuttal and said it would also start running ads in newspapers and websites, including The New York Times, The Wall Street Journal, Washington Post and NBC.com, that read, "Science. Not sensationalism." J&J also posted a video Monday of CEO Alex Gorsky reassuring consumers that the talc in its baby powder is safe.
But J&J's efforts may not be enough to ease weary consumers. On social media, people shared stories of their moms using J&J's baby product on themselves and their babies, worrying about the effects it may have.
"This does create a cloud of confusion," Jeffrey Sonnenfeld, senior associate dean for leadership studies & Lester Crown professor in the practice of management at the Yale School of Management, said Monday in an interview with CNBC's "Squawk on The Street."
Kristin Lewis, a mom of three young girls in Greenville, South Carolina, said she used J&J's baby powder when her first two daughters were babies to ward off diaper rashes. She chose the cornstarch version rather than the talc formula after researching and seeing concerns online. Eventually, she stopped using it because she didn't see a point, though she still keeps some in her house, she said.
Lewis, 37, hasn't used any of J&J's other name brand baby products on her girls. She said her pediatrician even told her to avoid the lavender-scented products because they include fragrances. Instead, she uses brands like The Honest Company and Babyganics.
"People gave (J&J lavender-scented products) to me for my baby shower and I gave them away to other people," Lewis told CNBC.
Sales of baby powder are a small slice of J&J's business. It accounts for less than 0.02 percent of J&J's sales, Citigroup analyst Amit Hazah said Friday in a note to clients. However, concerns about the baby powder may sow distrust in the company's other consumer products. J&J owns a number of skincare brands, including Aveeno and Neutrogena, as well as over-the-counter health products like Tylenol and Motrin.
The entire consumer segment posted $13.6 billion in sales last year, or 18 percent of J&J's $76.45 billion in total revenue, according to the company's financial statements. Pharmaceuticals accounted for $36.26 billion, or 47 percent of the company's sales, while medical devices accounted for $26.59 billion, or 35 percent of sales.
Analysts considered the stock sell-off overdone, saying these risks were well-known before the Reuters story. Multiple analysts said even if J&J settled all of the nearly 12,000 open cases settled, the costs could total a few billion, not nearly the amount of market capitalization J&J lost in one day Friday.
It may take time to see whether concerns over the company's baby powder scare consumers away from J&J's other consumer products. The company reports fourth-quarter earnings results Jan. 22.